VIDAZA® (Azacitidine) July 25, 2022July 25, 2022 RR FDA Approvals Myeloproliferative Disorders The FDA on May 20, 2022, approved VIDAZA® for pediatric patients with newly diagnosed Juvenile MyeloMonocytic Leukemia (JMML). VIDAZA® is a product of Celgene Corp. Related Posts:Long Term Overall Survival Benefit with VIDAZA® plus…Long Term Overall Survival Benefit with VIDAZA® plus…Efficacy of Low Dose Decitabine and Azacitidine in…TIBSOVO® and VIDAZA® Combo Improve Survival in…Efficacy and Safety in the Phase 3 QUAZAR® AML-001…Acute Myeloid Leukemia: Who Is an Appropriate…
